Posted by Michael Wonder on 19 Oct 2020
U.S. Food and Drug Administration accepts for priority review applications for Opdivo (nivolumab) in combination with Cabometyx (cabozantinib) in advanced renal cell carcinoma
19 October 2020 - U.S. Food and Drug Administration assigned a target action date of 20 February 2021.
Bristol Myers Squibb and Exelixis today announced that the U.S. FDA has accepted the supplemental biologics license application and supplemental new drug application, respectively, for Opdivo (nivolumab) in combination with Cabometyx (cabozantinib) for patients with advanced renal cell carcinoma.
